Conatus Pharmaceuticals Inc. (CNAT)

[biotech2010]

Ripley was promoted after being CNAT's lead in the NVTS negotiations and due diligence, it is a very clear sign that NVTS will exercise their option and move forward-the PR specifically says

“We expect his continued involvement to be instrumental in maintaining the collaborative relationship with Novartis as we advance through development, regulatory approvals and commercialization of our first-in-class, orally active pan-caspase inhibitor emricasan"

How much clearer than that can they be?